Insight Molecular Diagnostics Inc. (IMDX) — Relative ValuationPeer multiples, Monte Carlo simulation & quality-adjusted fair value
Insight Molecular Diagnostics Inc. (IMDX)
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 182 industry peers | $3.41 | -52.2% | 4% | B | Data |
| Price / Sales 184 industry peers | $2.85 | -60.1% | 3% | B | Model Driven |
| Weighted Output Blended model output | $6.23 | -12.7% | 100% | 48 | SLIGHTLY OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 11.95 | 15.26 | 3.74 | 16.85 | 7.15 |
| P/B Ratio | 4.74 | 3.35 | 0.90 | 15.26 | 5.37 |
| P/S Ratio | 56.57 | 37.13 | 12.73 | 128.69 | 50.20 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates IMDX's fair value at $6.23 vs the current price of $7.14, implying -12.7% downside potential. Model verdict: Slightly Overvalued. Confidence: 48/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $6.23 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%).
IMDX's current P/E of -1.5x compares to the industry median of 23.5x (45 peers in the group). This represents a -106.5% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
11 analysts cover IMDX with a consensus rating of Buy. The consensus price target is $9.00 (range: $9.00 — $9.00), implying +26.1% upside from the current price. Grade breakdown: Strong Buy (0), Buy (7), Hold (4), Sell (0), Strong Sell (0).
The model confidence score is 48/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for IMDX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.